83 related articles for article (PubMed ID: 8373443)
1. Enhancement of tumouricidal activity of daunomycin by receptor-mediated delivery. In vivo studies.
Mukhopadhyay B; Mukhopadhyay A; Basu SK
Biochem Pharmacol; 1993 Sep; 46(5):919-24. PubMed ID: 8373443
[TBL] [Abstract][Full Text] [Related]
2. Scavenger-receptor-mediated delivery of daunomycin elicits selective toxicity towards neoplastic cells of macrophage lineage.
Mukhopadhyay A; Mukhopadhyay B; Srivastava RK; Basu SK
Biochem J; 1992 May; 284 ( Pt 1)(Pt 1):237-41. PubMed ID: 1599401
[TBL] [Abstract][Full Text] [Related]
3. Circumvention of multidrug resistance in neoplastic cells through scavenger receptor mediated drug delivery.
Mukhopadhyay A; Mukhopadhyay B; Basu SK
FEBS Lett; 1995 Nov; 376(1-2):95-8. PubMed ID: 8521976
[TBL] [Abstract][Full Text] [Related]
4. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. II. Evaluation of daunomycin conjugates in vivo against L1210 leukaemia.
Duncan R; Kopecková P; Strohalm J; Hume IC; Lloyd JB; Kopecek J
Br J Cancer; 1988 Feb; 57(2):147-56. PubMed ID: 3358905
[TBL] [Abstract][Full Text] [Related]
5. Killing of intracellular Mycobacterium tuberculosis by receptor-mediated drug delivery.
Majumdar S; Basu SK
Antimicrob Agents Chemother; 1991 Jan; 35(1):135-40. PubMed ID: 1901694
[TBL] [Abstract][Full Text] [Related]
6. Enhanced intracellular delivery of doxorubicin by scavenger receptor-mediated endocytosis for preferential killing of histiocytic lymphoma cells in culture.
Basu S; Mukhopadhyay B; Basu SK; Mukhopadhyay A
FEBS Lett; 1994 Apr; 342(3):249-54. PubMed ID: 8150079
[TBL] [Abstract][Full Text] [Related]
7. Selective delivery of drugs to macrophages through a highly specific receptor. An efficient chemotherapeutic approach against leishmaniasis.
Chaudhuri G; Mukhopadhyay A; Basu SK
Biochem Pharmacol; 1989 Sep; 38(18):2995-3002. PubMed ID: 2783154
[TBL] [Abstract][Full Text] [Related]
8. Daunorubicin-albumin copolymer targeting to leukemic cells in vitro and in vivo.
Lagueux J; Pagé M; Delorme F
Semin Oncol; 1984 Dec; 11(4 Suppl 3):59-63. PubMed ID: 6505719
[No Abstract] [Full Text] [Related]
9. Pharmacological and therapeutic efficacy of daunomycin:DNA complex in mice.
Ohnuma T; Holland JF; Chen JH
Cancer Res; 1975 Jul; 35(7):1767-72. PubMed ID: 1131831
[TBL] [Abstract][Full Text] [Related]
10. Scavenger receptor-mediated delivery of muramyl dipeptide activates antitumor efficacy of macrophages by enhanced secretion of tumor-suppressive cytokines.
Srividya S; Roy RP; Basu SK; Mukhopadhyay A
J Leukoc Biol; 2000 May; 67(5):683-90. PubMed ID: 10811009
[TBL] [Abstract][Full Text] [Related]
11. Drug targeting in cancer treatment: active daunorubicin-protein conjugates.
Deprez-de Campeneere D; Masquelier M; Baurain R; Trouet A
Prog Clin Biol Res; 1982; 102 pt A():291-8. PubMed ID: 7167441
[No Abstract] [Full Text] [Related]
12. Leukemic cell and plasma daunomycin concentrations after bolus injection and 72 h infusion.
Speth PA; Linssen PC; Boezeman JB; Wessels HM; Haanen C
Cancer Chemother Pharmacol; 1987; 20(4):311-5. PubMed ID: 3690804
[TBL] [Abstract][Full Text] [Related]
13. Sugar receptor mediated drug delivery to macrophages in the therapy of experimental visceral leishmaniasis.
Chakraborty P; Bhaduri AN; Das PK
Biochem Biophys Res Commun; 1990 Jan; 166(1):404-10. PubMed ID: 2302213
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of P-glycoprotein-mediated daunomycin transport in rat liver canalicular membrane vesicles.
Kwon Y; Kamath AV; Morris ME
J Pharm Sci; 1996 Sep; 85(9):935-9. PubMed ID: 8877882
[TBL] [Abstract][Full Text] [Related]
15. [Experimental studies on the therapy of rat myelomonocytic leukemia with lipopolysaccharide (LPS) and daunomycin (DM)].
Fujii Y
Hokkaido Igaku Zasshi; 1985 Sep; 60(5):735-47. PubMed ID: 3865874
[TBL] [Abstract][Full Text] [Related]
16. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat.
Huwyler J; Yang J; Pardridge WM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1541-6. PubMed ID: 9316870
[TBL] [Abstract][Full Text] [Related]
17. Erythrocyte membrane-bound daunorubicin as a delivery system in anticancer treatment.
Gaudreault RC; Bellemare B; Lacroix J
Anticancer Res; 1989; 9(4):1201-5. PubMed ID: 2817803
[TBL] [Abstract][Full Text] [Related]
18. Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes.
Versluis AJ; Rensen PC; Rump ET; Van Berkel TJ; Bijsterbosch MK
Br J Cancer; 1998 Dec; 78(12):1607-14. PubMed ID: 9862571
[TBL] [Abstract][Full Text] [Related]
19. In vivo cytotoxicity and antineoplastic activity of a transferrin-daunorubicin conjugate.
Lemieux P; Pagé M; Noël C
In Vivo; 1992; 6(6):621-7. PubMed ID: 1296812
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection.
Anatelli F; Mroz P; Liu Q; Yang C; Castano AP; Swietlik E; Hamblin MR
Mol Pharm; 2006; 3(6):654-64. PubMed ID: 17140253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
